Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$91.96

1.48 (1.64%)

, IONS

Ionis Pharmaceuticals

$58.70

0.94 (1.63%)

06:55
11/18/19
11/18
06:55
11/18/19
06:55

Piper Jaffray biotech analysts to hold an analyst/industry conference call

Biotech Analysts Van Buren, Bancroft and Duncan review the AG10 Phase II OLE data and the echo and biomarker data (TTR, Tnl, BNP) and what implications it has for patients on an Analyst/Industry conference call to be held on November 18 at 7:30 am.

ALNY

Alnylam

$91.96

1.48 (1.64%)

IONS

Ionis Pharmaceuticals

$58.70

0.94 (1.63%)

AKCA

Akcea Therapeutics

$19.30

0.22 (1.15%)

PFE

Pfizer

$37.28

0.73 (2.00%)

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

  • 18

    Nov

  • 21

    Nov

  • 21

    Nov

  • 22

    Nov

  • 07

    Dec

  • 04

    Feb

ALNY Alnylam
$91.96

1.48 (1.64%)

11/10/19
PIPR
11/10/19
NO CHANGE
PIPR
Piper Jaffray reiterates Overweight on Alnylam after data presentation
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $145 price target on Alnylam after the company initiated its Phase III ILLUMINATE-C trial of lumasirin in primary hyperoxaluria type 1 patients with advanced renal disease and presented Phase II open-label extension data showing "lumasirin reduced urinary oxalate excretion 76% from Phase I/II baseline levels." Tenthoff said that Alnylam will report Phase III ILLUMINATE-A data on lumasiran by the end of the year. The analyst forecast 2019 Onpattro sales of $160M that will grow to $330M in 2020, and noted that Onpattro and nextgen vutrisiran are being evaluated in Phase III cardiomyopathy trials that could expand the Onpattro label by 2021/'22. Tenthoff added that he is confident in givosiran getting FDA approval, and noted its has a PDUFA date of February 4 with no expected AdComm.
11/13/19
BOFA
11/13/19
INITIATION
Target $110
BOFA
Buy
Alnylam initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated coverage of Alnylam Pharmaceuticals with a Buy rating and $110 price target. The analyst views the company as a "key stakeholder" in RNA silencing technology with an "attractive blend" of commercial and late-stage rare disease pipeline.
09/10/19
PIPR
09/10/19
NO CHANGE
Target $145
PIPR
Overweight
Alnylam's updated OLE data shows reduced 'daily worst pain,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $145 price target on Alnylam after the company presented new results from the Phase III ENVISION trial and Phase I/II OLE study of givosiran in Acute Hepatic Poprphyria at the International Congress on Porphyrins and Porphyrias Conference. Tenthoff says the updated OLE data showed that monthly givosiran dosing reduced median annualized attack rate to 0.22 over 30 months, and patient reported outcomes also revealed reduced "daily worst pain" for subjects receiving givosiran, lower use of opioids and improved quality of life. Tenthoff tells investors in a research note that he is "confident" in FDA approval by the February 4 PDUFA date.
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
IONS Ionis Pharmaceuticals
$58.70

0.94 (1.63%)

11/07/19
MSCO
11/07/19
DOWNGRADE
Target $48
MSCO
Underweight
Morgan Stanley downgrades Ionis to Underweight ahead of 'challenging' 2020
As previously reported, Morgan Stanley analyst David Lebowitz downgraded Ionis Pharmaceuticals to Underweight from Equal Weight with a price target of $48, down from $63, citing what he sees as a lack of near-term catalysts and what he thinks will be a "challenging" year ahead. While he acknowledges Spinraza remains strong, the company reported weak results from Tegsedi yesterday and Lebowitz doesn't think its pipeline appears ready with a next "break-out therapy" despite having over 40 clinical stage candidates.
11/13/19
BOFA
11/13/19
INITIATION
Target $70
BOFA
Buy
Ionis Pharmaceuticals initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated coverage of Ionis Pharmaceuticals with a Buy rating and $70 price target. The analyst sees a favorable risk/reward profile ahead of the company's 2020 data catalysts. Further, he believes the rollout of new product driven royalty streams puts Ionis in a strong financial position.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
Ionis Pharmaceuticals initiated with a Market Perform at William Blair
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.
AKCA Akcea Therapeutics
$19.30

0.22 (1.15%)

10/07/19
10/07/19
UPGRADE
Target $25

Outperform
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the partnership of AKCEA-ANGPTL3-Lrx with Pfizer (PFE) for development in cardiovascular and metabolic disease indications. The analyst views the partnership as validating of the ANGPTL3 opportunity, with terms "highly favorable" to Akcea, significant market opportunity in NAFLD/NASH/CVD and upfront cash supportive of increased investment in TEGSEDI commercialization, preparation for TTR-LICA and externally focused business development. Birchenough also raised his price target on Akcea's shares to $25 from $24.
10/07/19
STFL
10/07/19
NO CHANGE
Target $31
STFL
Hold
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
Stifel analyst Paul Matteis called Akcea Therapeutics' (AKCA) licensing agreement for AKCEA-ANGPTL3-LRx with Pfizer (PFE) a "solid and unexpected win" for the former in the wake of recent management turnover. Pfizer will pay up to $1.3B in milestones, including $250M in cash upfront, noted Matteis, who does not think investors were ascribing "all that much credit" to this asset. Matteis has a Hold rating on Akcea shares with a $31 price target.
10/08/19
BMOC
10/08/19
NO CHANGE
Target $39
BMOC
Outperform
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Akcea Therapeutics (AKCA) to $39, noting that while the company's announcement of a Pfizer (PFE) licensing deal yesterday provides "immediate value" to its third lipid asset, the disclosure of a management transition increases the risk of potential disruptions in commercial operations. The analyst still keeps his Outperform rating on the stock, citing significant upside optionality from its "underappreciated pipeline assets" with multiple catalysts expected in the next six months that could unlock value for shareholders.
10/07/19
WELS
10/07/19
UPGRADE
WELS
Outperform
Akcea Therapeutics upgraded to Outperform from Market Perform at Wells Fargo
PFE Pfizer
$37.28

0.73 (2.00%)

10/22/19
WEDB
10/22/19
NO CHANGE
Target $186
WEDB
Outperform
Ascendis Pharma price target lowered to $186 from $191 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Ascendis Pharma (ASND) to $186 from $191 after competitors Opko Health (OPK) and Pfizer (PFE) announced topline results from a global Phase 3 trial evaluating somatrogon in pre-pubertal children with growth hormone deficiency. Given, Pfizer's role in registering and commercializing somatrogon, the analyst can see a potentially similar regulatory timeline to Ascendis, noting that the latter anticipates BLA and MAA submissions in the first half and second half of 2020, respectively. Nonetheless, Moussatos reiterates an Outperform rating on Ascendis shares as she remains positive on TC-hGH despite competition.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $70
PIPR
Neutral
Ionis Pharmaceuticals price target lowered to $70 from $75 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target on Ionis Pharmaceuticals (IONS) to $70 and kept his Neutral rating after its Q3 results, saying that while the quarter was "strong" thanks to the recent $250M upfront payment from Pfizer (PFE), results for its Tegsedi were "uninspiring". The analyst states that an acceleration in Tegsedi is needed soon for him to become more positive on the name ahead of the "potential Phase I/II OLE +natural history Huntington's study readouts next year."
11/12/19
PIPR
11/12/19
NO CHANGE
Target $185
PIPR
Overweight
Time to dismiss Solid Biosciences as Sarepta competitor, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says that while she had dismissed Solid Biosciences' (SLDB) microdystophin gene therapy program as a competitive threat to Sarepta Therapeutics (SRPT), some investors worried that Solid could provide compelling data after adjusting protocol and moving up the dose. However, today's report of another clinical hold confirms that Solid's construct is toxic, indicating that Pfizer's (PFE) may to too, Brill tells investors in a research note. The analyst points out that both Solid and Pfizer use AAV9 and have had complement mediated serious adverse events after dosing just a few patients. Solid's program reaffirms her view that Sarepta's safety profile is differentiated. It is unlikely that the competition "is viable, let alone will ever catch up," says Brill. She keeps an Overweight rating on Sarepta Therapeutics with a $185 price target. The stock in midday trading is up 4% to $99.02 while Solid Biosciences is down 71% to $3.22.
BBIO BridgeBio
$28.26

0.55 (1.98%)

10/18/19
PIPR
10/18/19
NO CHANGE
Target $50
PIPR
Overweight
BridgeBio has 'best-in-class' potential in achondroplasia, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating on BridgeBio with a $50 price target after new preclinical data for infigratinib in achondroplasia were presented. The drug is effective at lower and less frequent dosing regimens than previously tested, says the analyst, who believes infigratinib could capture 50% achondroplasia market share by 2035, which could amount to over $1.5B in sales. He sees "best-in-class potential" for the drug.
07/26/19
07/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dentsply Sirona (XRAY) initiated with an In Line at Evercore ISI. 2. BridgeBio (BBIO) initiated with an Outperform at Raymond James. 3. Crispr Therapeutics (CRSP) initiated with a Buy at Canaccord. 4. GeoPark (GPRK) initiated with a Buy at GMP Securities. 5. Neon Therapeutics (NTGN), Gritstone Oncology (GRTS), and Cue Biopharma (CUE) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/19
BTIG
09/13/19
NO CHANGE
Target $56
BTIG
Buy
Eidos Therapeutics price target raised to $56 from $38 at BTIG
BTIG analyst Thomas Shrader raised his price target on Eidos Therapeutics (EIDX) to $56 and kept his Buy rating after the decision by its board to reject an acquisition offer from parent company BridgeBio (BBIO) to buy all of its outstanding stock. The analyst notes that he always believed the combined entity would not be a more attractive investment, saying he is positive on the company's "declaration of independence". Shrader further cites the added revenue contribution expected from Eidos Therapeutics' deal with Alexion (ALXN) to develop and commercialize AG10 in Japan.
07/26/19
RAJA
07/26/19
INITIATION
Target $36
RAJA
Outperform
Raymond James starts BridgeBio at Outperform with $36 price target
As previously reported, Raymond James analyst Dane Leone initiated BridgeBio with an Outperform rating and $36 price target. His Outperform rating is mostly predicated upon the company's key programs for TTR amyloidosis, cholangiocarcinoma and urothelial carcinoma and achondroplasia, Leone stated, adding that the company is unique in the way its project management team incentive compensation is aligned with the outcomes of the specific drugs they are working on.
EIDX Eidos Therapeutics
$46.58

1.33 (2.94%)

11/01/19
ROTH
11/01/19
NO CHANGE
Target $57
ROTH
Buy
Eidos Therapeutics price target raised to $57 from $51 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics to $57 from $51 and keeps a Buy rating on the shares. Yesterday's Q3 earnings report was "plain vanilla," with ATTRibute-CM enrollment continuing and plans to initiate a Ph3 ATTR-PN study in Q1, Rahimi tells investors in a post-earnings research note. The analyst maintains her "strong conviction" in AG10 as a best-in-class transthyretin stabilizer.
11/01/19
LEHM
11/01/19
DOWNGRADE
Target $45
LEHM
Equal Weight
Barclays downgrades Eidos Therapeutics on valuation after recent run
Barclays analyst Gena Wang downgraded Eidos Therapeutics to Equal Weight from Overweight with a price target of $45, up from $37. While the analyst believes a "meaningful commercial opportunity" exists for AG-10 given the large ATTR-CM market, she sees limited upside after the stock's recent run. Further, there's a lack of meaningful catalysts for Eidos until the Phase 3 topline data from Part A in 2021, Wang tells investors in a research note.
11/17/19
PIPR
11/17/19
NO CHANGE
PIPR
Piper Jaffray sees Eidos shares rising following AHA presentation
Piper Jaffray analyst Tyler Van Buren maintained an Overweight rating and $55 price target on Eidos Therapeutics following "positive" data from the ongoing Phase II OLE presented at the American Heart Association, or AHA, which suggests that "AG10 may be providing patients with superior long-term outcomes relative to Vyndaqel/tafamidis." Van Buren believes these results suggest that AG10 could be "the best-in-class TTR stabilizer" and the analyst now has a "higher level of confidence in the probability of success of the ongoing Phase III trial."
11/01/19
LEHM
11/01/19
DOWNGRADE
Target $45
LEHM
Equal Weight
Eidos Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Eidos Therapeutics to Equal Weight from Overweight with a $45 price target.

TODAY'S FREE FLY STORIES

FITB

Fifth Third

$30.24

0.365 (1.22%)

, CSCO

Cisco

$43.83

0.29 (0.67%)

18:37
12/06/19
12/06
18:37
12/06/19
18:37
Hot Stocks
Fifth Third issues statement on temporary network outage »

Fifth Third Bank (FITB)…

FITB

Fifth Third

$30.24

0.365 (1.22%)

CSCO

Cisco

$43.83

0.29 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33
Hot Stocks
Stemline names Robert Francomano as Chief Commercial Officer »

Most recently, Francomano…

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

GOL

Gol Linhas

$17.39

1.07 (6.56%)

18:31
12/06/19
12/06
18:31
12/06/19
18:31
Hot Stocks
Gol Linhas announces preliminary traffic figures for November »

GOL's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.97

0.07 (7.78%)

18:25
12/06/19
12/06
18:25
12/06/19
18:25
Syndicate
Navidea announces $1.9M private placement »

Navidea announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$18.22

0.09 (0.50%)

18:23
12/06/19
12/06
18:23
12/06/19
18:23
Hot Stocks
Ellington Financial reports estimated book value per share $18.51 on November 30 »

This estimate includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$41.93

0.81 (1.97%)

18:22
12/06/19
12/06
18:22
12/06/19
18:22
Hot Stocks
Boot Barn CEO: More than 80% of our business is in the store »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$9.24

0.1 (1.09%)

18:18
12/06/19
12/06
18:18
12/06/19
18:18
Hot Stocks
Ericsson to pay over $1B to settle FCPA case »

Ericsson has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GLD

SPDR Gold Shares

$137.59

-1.42 (-1.02%)

17:55
12/06/19
12/06
17:55
12/06/19
17:55
Hot Stocks
SPDR Gold Shares holdings fall to 886.23MT from 888.57MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PICO

PICO Holdings

$10.81

0.31 (2.95%)

17:45
12/06/19
12/06
17:45
12/06/19
17:45
Hot Stocks
PICO Holdings sells long-term storage credits for $8.7M in Arizona »

PICO Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QHC

Quorum Health

$0.95

0.0522 (5.81%)

17:31
12/06/19
12/06
17:31
12/06/19
17:31
Hot Stocks
Quorum Health receives NYSE continued listing standard notice »

Quorum Health Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:30
12/06/19
12/06
17:30
12/06/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.69

0.34 (5.35%)

17:29
12/06/19
12/06
17:29
12/06/19
17:29
Syndicate
Breaking Syndicate news story on Baudax Bio »

Baudax Bio files $125M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

LMT

Lockheed Martin

$387.10

1.175 (0.30%)

17:25
12/06/19
12/06
17:25
12/06/19
17:25
Hot Stocks
Lockheed Martin awarded $153.39M Navy contract modification »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENV

Envestnet

$71.72

1.27 (1.80%)

17:23
12/06/19
12/06
17:23
12/06/19
17:23
Syndicate
Breaking Syndicate news story on Envestnet »

Envestnet files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$344.79

0.4 (0.12%)

17:20
12/06/19
12/06
17:20
12/06/19
17:20
Hot Stocks
Northrop Grumman awarded $189M Navy contract modification »

Northrop Grumman was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:03
12/06/19
12/06
17:03
12/06/19
17:03
Hot Stocks
Support.com announces special distribution of $1.00 per share »

The record date for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:01
12/06/19
12/06
17:01
12/06/19
17:01
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RZLT

Rezolute

$0.00

(0.00%)

17:00
12/06/19
12/06
17:00
12/06/19
17:00
Syndicate
Breaking Syndicate news story on Rezolute »

Rezolute files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

16:58
12/06/19
12/06
16:58
12/06/19
16:58
Periodicals
U.S. mulls putting Amazon foreign sites on 'Notorious Markets' list, WSJ says »

The Trump administration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

16:55
12/06/19
12/06
16:55
12/06/19
16:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

IMH

IMPAC Mortgage

$5.63

-0.01 (-0.18%)

16:54
12/06/19
12/06
16:54
12/06/19
16:54
Syndicate
Breaking Syndicate news story on IMPAC Mortgage »

IMPAC Mortgage files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALEC

Alector

$19.74

0.33 (1.70%)

16:32
12/06/19
12/06
16:32
12/06/19
16:32
Hot Stocks
Alector reports Phase 1 safety, biomaker data on AL002 »

Alector reported safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATAX

America First Multifamily Investors

$7.58

0.125 (1.68%)

16:31
12/06/19
12/06
16:31
12/06/19
16:31
Hot Stocks
America First Multifamily Investors CFO Craig Allen to retire »

On December 2,Craig Allen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
12/06/19
12/06
16:30
12/06/19
16:30
Options
Preliminary option volume of 20.4M today »

Preliminary option volume…

PNM

PNM Resources

$48.77

-0.06 (-0.12%)

16:29
12/06/19
12/06
16:29
12/06/19
16:29
Hot Stocks
PNM Resources raises quarterly dividend 6% to 30.75c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.